Publications

5677 Results

Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial

Authors
R Krouse;G Anderson;K Arnold;C Thomson;V Nfonsam;M Al-Kasspooles;J Walker;V Sun;A Alvarez Secord;E Han;A Leon-Takahashi;D Isla Ortiz;P Rodgers;S Hendren;M Sanchez Salcedo;J Laryea;W Graybill;D Flaherty;H Mogal;T Miner;J Pimiento;M Kitano;B Badgwell;G Whalen;J Lamont;O Guevara;M Senthil;S Dewdney;E Silberfein;J Wright;B Friday;B Fahy;S Anantha;M O'Rourke;M Bakitas;J Sloan;M Grant;G Deutsch;J Deneve
Journal / Conference
Lancet Gastroenterology and Hepatology Aug 1;S2468-1253(23)00191-7
Year
2023
Research Committee(s)
Palliative Care
PMID
PMID37541263
PMC
PMC10530384
Study Number(s)
S1316

Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial

Authors
N Sayegh;U Swami;Y Jo;C Tangen;G Gebrael;B Haaland;S Gupta;M Plets;M Hussain;D Quinn;P Lara;IM Thompson;N Agarwal
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 6532); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1216

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by Total Mesorectal Excision (TME) for treatment of locally advanced rectal cancer (LARC)

Authors
D Schrag;S Quian;M Weiser;M Gollub;L Saltz;G Chang;R Auer;J Farma;T George;V Gordon;B Musher;J Goldberg;T Kolevska;A Dueck;E Basch;A Venook;K Goodman;E O'Reilly;J Meyerhardt;H Mamon
Journal / Conference
J Clin Oncol 41, 2023 (suppl 17; abstr LBA2); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), plenary session - oral
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/N1048

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): results from the Phase III SWOG S1216 trial of androgen deprivation +/- orteronel

Authors
P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;M LeBlanc;I Thompson;N Agarwal
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 5048); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1216

SWOG S1011 - A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer

Authors
SP Lerner;C Tangen;R Svatek;S Daneshmand;K Pohar;E Skinner;A Schuckman;A Sagalowsky;N Smith;A Kamat;W Kassouf;M Plets;R Bangs;T Koppie;A Alva;F La Rosa;S Pal;A Kibel;D Canter;I Thompson
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 4508); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1011

A021804: A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

Authors
J Del Rivero;K Perez;S Geyer;M Khalil;A Vijendran;A Kordaris-Corkill;A Shegrill;H Soares;C Lopez;A Nixon;A Dueck;J Meyerhardt;E O'Reilly
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4191); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/A021804

Results of a Phase 3 study of IVO vs IO for Previously Untreated Older Patients with CLL and Impact of COVID-19

Authors
J Woyach;J Yin;J Brown;S Dinner;G Lozanski;R Little;C Miller;S Coutre;W Ding;B Hill;G Perez;A Ruppert;A Wall;D Feldman;E Dib;H Erba;R Stone;J Byrd
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 7500); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
Year
2023
Research Committee(s)
Leukemia

A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer - evaluating radiation, ablation, and surgery (ERASur)

Authors
K Hitchcock;P Romesser;Q Shi;J Dixon;S Gholami;S White;C Wu;C Goulet;K Jee;C Wright;R Yaeger;A Shergill;T Hong;T George;E O'Reilly;J Meyerhardt;E Miller
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3629); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A022101

A multicenter phase II study of cabozantinib + nivolumab for patients with advanced angiosarcoma previously treated with a taxane (Alliance A091902)

Authors
J Olson;J Allred;S Schuetze;E Davis;A Poklepovic;M Wagner;B Waechter;R Reidel;M Xu-Welliver;S Berg;S George;S Robinson;P Googe;S DAngelo;G Schwartz
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 11503); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
Year
2023

A022104/NRG-GI010: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER | THE JANUS RECTAL CANCER TRIAL

Authors
JJ Smith;A Dasari;Q Shi;J Garcia-Aguilar;H Sanoff;T George;T Hong;G Yothers;P Philip;G Nelson;T Al Baghdadi;E O'Reilly;J Meyerhardt;A Shergill;N Horvat;P Romesser;W Hall
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3640); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Gastrointestinal